Medical Devices Startups
5,183 companies tagged Medical Devices, with their investors and founders.
Thrivable delivers patient insights and data to healthcare organizations to support product adoption and retention decisions. The company provides real-time access to a database of patients with chronic conditions, using AI-powered analytics to help healthcare leaders understand patient experiences.
6 investors
Ultromics develops FDA-cleared AI software (EchoGo Heart Failure and EchoGo Amyloidosis) that analyzes routine echocardiograms to help clinicians identify patients with HFpEF and screen for cardiac amyloidosis. The platform integrates with existing ultrasound and PACS systems for hospitals and echo labs, primarily in the U.S.
6 investors
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
6 investors
VitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics. It targets healthcare providers and patients seeking point-of-care diagnostic testing.
6 investors
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
6 investors
ZETA Surgical makes a cranial navigation system for neurosurgical procedures including ventriculostomy, brain biopsy, and transcranial magnetic stimulation in operating rooms and interventional suites. The company serves neurosurgeons and healthcare systems.
6 investors
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.
6 investors
Oxford Cancer Analytics develops a diagnostics platform that combines reproducible proteomic measurement with AI to produce evidence-based insights supporting clinical decision-making. Its focus is on lung disease, beginning with Chronic Obstructive Pulmonary Disease (COPD) and extending to conditions such as lung cancer.
5 investors
STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells. The platform enables in vivo genetic medicines with an initial focus on rare hematological diseases and CAR-T therapies, supporting approaches such as gene editing, RNA therapeutics, and immune cell engineering.
5 investors
410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation. The device is aimed at hospital and emergency care settings for fluid resuscitation workflows.
5 investors
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
5 investors
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
5 investors
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.
5 investors
Adyn uses large inclusive datasets and machine learning to advance personalized medicine for historically under-researched health conditions, with initial focus on reproductive disorders. The company aims to close race and gender knowledge gaps in medical research.
5 investors
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases. The company focuses on advancing transformative treatments in areas including oncology, rare genetic diseases, and cell therapies.
5 investors
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease. The company serves eye care professionals and patients in the global ophthalmic pharmaceutical market.
5 investors
Aether Biomedical develops the Zeus multi-articulating bionic hand and an ecosystem of prosthetic devices, control systems, and connected digital tools. Its products serve upper-limb prosthetic users and the clinicians who fit and support them.
5 investors
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
5 investors
Alimetry develops the Gastric Alimetry system, a non-invasive body surface gastric mapping device that provides objective diagnostics for patients with chronic gastrointestinal symptoms. It is used by hospitals and GI clinicians, with availability in New Zealand, Australia, the UK, and the US.
5 investors
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease. The company focuses on pharmaceutical development and clinical research in the cardiovascular health sector.
5 investors
Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
5 investors
AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
5 investors
AOI Biosciences is a Japanese biotech company focused on infectious diseases and autoimmune disorders, combining data analysis technology with proprietary bio-technology. It operates diagnostic testing, drug discovery, and drug discovery support businesses.
5 investors
ShipArty builds IoT-enabled temperature-controlled containers and software platform to reduce cold chain spoilage for medicines, vaccines, and other temperature-sensitive products. The company offers reusable, sustainable alternatives to single-use cooling systems for pharmaceutical and healthcare supply chains.
5 investors